PTC Therapeutics | PTCT - Selling And Administration Expenses



PTC Therapeutics reported $85.26M in Selling and Administration Expenses for its fiscal quarter ending in June of 2025.


Selling And Administration Expenses Change Date
Acadia Pharmaceuticals USD 123.66M 2.71M Jun/2025
Alnylam Pharmaceuticals USD 323.31M 83.36M Jun/2025
Amgen USD 1.69B 4M Jun/2025
Biogen USD 583.8M 11.3M Jun/2025
BioMarin Pharmaceutical USD 232.28M 26.16M Jun/2025
Cytokinetics USD 65.72M 8.35M Jun/2025
Daiichi Sankyo JPY 180.35B 27.86B Jun/2025
Gilead Sciences USD 1.36B 100M Jun/2025
Incyte USD 331.02M 5.33M Jun/2025
Ionis Pharmaceuticals USD 90.6M 14.6M Jun/2025
Ironwood Pharmaceuticals USD 33.33M 2.78M Dec/2024
Novartis USD 3.44B 384M Jun/2025
Pfizer USD 3.42B 406M Jun/2025
PTC Therapeutics USD 85.26M 76.66M Jun/2025
Roche Holding CHF 3.61B 381M Dec/2024
Sarepta Therapeutics USD 69.89M 63.74M Jun/2025
TG Therapeutics USD 12.04M 38.29M Jun/2025
Ultragenyx Pharmaceutical USD 86.65M 1.15M Jun/2025
Vertex Pharmaceuticals USD 424.6M 28.2M Jun/2025
Xencor USD 15.11M 2.22M Jun/2025